coffe hold co inc jva buy pt maintain buy rais pt better-than-expect result
dividend announc potenti cbd coffe launch analyst stephen anderson full summari
margin stabil maintain buy pt analyst stephen anderson full summari
trovagen inc trov buy pt fund secur advanc onvansertib third indic metastat colorect
corpor event call maxim salesperson inform
charl colvard ltd cthr ndr new york ceo/presid suzann miglucci cfo clint pete tue feb
sintx technolog inc sint ndr new york ceo sonni bal vice-president oper david brian mon-tu
bioporto a/ biopor ndr new york ceo peter morch cfo ole larson fri feb
chesapeak util corpor cover sullivan ndr milwauke cfo beth cooper treasur
chesapeak util corpor cover sullivan ndr chicago cfo beth cooper treasur
gse system gvp cover sullivan ndr new york ceo kyle loudermilk chri sorrel tue
cover sullivan ndr boston ceo denni sadlowski cfo matthew
navig hold ltd nvg cover jang group luncheon new york ceo david butter thu
pm
cover jang ndr boston ceo gari vogel cfo frank decostanzo
director strategi busi develop costa tsoutsoplid tue apr
maxim group senior enterpris consum technolog analyst nehal chokshi market day nyc wed jan
univers mcloud corpor mcld cover chokshi ndr seattl ceo russ mcmeekin mon feb
univers mcloud corpor mcld cover chokshi ndr new york ceo russ mcmeekin mon-w
corpor ctrl cover chokshi ndr chicago cfo mark novakovich mon feb
corpor ctrl cover chokshi ndr boston cfo mark novakovich tue feb
cover klee ndr chicago presid ceo michael prior cfo justin
cover klee ndr milwauke presid ceo michael prior cfo
servic gm q/q y/i trajectori disclosur paint posit pictur
product gm trend even concern
instal base disclosur y/i basi fail assuag fear china
iphon instal base declin
guidanc indic deterior busi fundament
reiter hold rate price target
servic gm q/q y/i trajectori disclosur paint posit pictur product
gm trend even concern report decemb quarter result
consist neg pre-announc detail key final number includ
revenu china y/i given bulk shortfal iphon relat
estim china iphon revenu y/i vs overal iphon
y/i servic gm y/i q/q product
gm y/i though q/q due volum favor
compon price high increas servic gm solidifi idea
sell low margin devic product revenu collect higher margin annuiti
servic revenu grew per user number activ devic also
grew y/i iphon instal base grew y/i decemb howev
nullifi content quarterli valu servic revenu per activ devic
grew y/i use activ instal devic base
disclosur remain small versu estim iphon annuiti use
year refresh cycl plu like anoth ipad watch annuiti
product gm declin past
year see figur page overal gm declin
concern product gm fall level differenti
hardwar continu fade servic gm declin aapl nativ subscript
servic ramp servic revenu music upcom long-form video news
servic like carri much lower servic gm see figur
downgrad analysi revenu stream
instal base disclosur y/i basi fail assuag fear china
iphon instal base declin disclos iphon activ
instal base increas year ago current y/i
y/i growth activ iphon instal base achiev report
region includ greater china howev note materi portion
increment activ unit past year like low-end user high-
end iphon user trade-in year old phone get re-sold new
iphon user much lower dispos incom like repres lower servic
arpu custom well addit note revenu greater china
decemb quarter iphon user base like
grew q/q decemb septemb given
declin china revenu dec believ remain like
greater china iphon instal base begun contract
guidanc indic deterior busi fundament
guidanc midpoint y/i consensu
estim deterior y/i declin report
decemb manag note channel inventori within target
level thu believ deterior y/i trajectori like result demand
worsen y/i basi rather posit perspect greater
usual channel drain due disappoint decemb quarter result manag
guid opex q/q impli midpoint ep
prior consensu estim
reiter hold rate price target provid rise
nation play weak result china remain concern
instal base greater china iphon user take multi-year process re-
size similar took multi-year process consum pc instal base
re-siz result transfer workload pc tablet mainli ipad
continu assum iphon unit declin y/i remaind
y/i also assum instal
base contract per year next three year non-aapl nativ subscript
servic pay music icloud forthcom news video
declin per year next three year well result project
revenu declin end revenu stabil
result project ep bottom thu use
price target basi addit given materi risk face iphon
instal base declin multipl year use multipl rather
standard in-lin hdd multipl use seagat
stx hold buy compar
given unchang price target input includ ep estim
price target remain
click full note
expect margin stabil maintain buy
maintain buy rate price target
follow releas decemb result yesterday
margin actual chang littl y/i basi expect margin
stabil
march ep estim unchang vs consensu
though rais june ep estim vs
consensu ep estim vs
margin actual chang littl y/i basi expect margin
stabil acknowledg investor concern declin
restaurant-level ebitda margin profound declin
septemb howev two factorsth chang treatment franchis
revenu advertis contribut chang expens treatment
 higher leas expens follow august sale-lease-back transact
togeth account declin third factormanag decis
increas restaurant-level manag compensationaccount addit
declin three factor like affect y/i margin chang
repeat leav y/
restaurant-level ebitda margin declin attribut half
higher y/i employe healthcar expens tend volatil quarter
quarter strip factor leav y/i restaurant-level
ebitda margin declin view nomin invest chili
ttm sale return posit traffic model rel stabl
restaurant-level ebitda margin head lap roll-out chili
menu platform though rule potenti return
margin expans given opportun restaurant-level effici gain
 menu simplif potenti back-of-hous labor save renov
upsel opportun monthli margarita modest sg expens
increas manag regard platform reduc need
march ep estim unchang though rais
june ep estim ep estim
revis blend comp assumpt
model blend comp firmli posit rang
base discuss manag call believ
comp gain chili maggiano come expens independ
smaller-chain restaur
compel valuat yesterday pullback coupl one
highest short posit univers share trade forward price-to-earnings
full-servic dine averag forward ev/ebitda
base estim unchang price target impli forward whole-
compani price-to-earnings vs five-year averag forward ev/ebitda
vs five-year averag one highest short posit
coverag univers float compar weight industri
averag believ continu posit result potenti trigger short-
click full note
fund secur advanc onvansertib third
trovagen announc enter agreement poc capit
fund clinic develop lead asset onvansertib polo-lik kinas
inhibitor inhibitor phase clinic trial patient
onvansertib advanc third clinic program
acut myeloid leukemia aml studi combin ldac
decitabin on-going reach maximum toler dose
dose come enrol complet data
mcrpc prostat cancer combin abirateron complet
enrol data expect data readout
particularli interest drug like abirateron move earlier
line therapi thu extend time drug avoid move
iv chemo could signific pc space view
colorect cancer initi mcrc studi combin
folfiri avastin
conclus secur fund third indic ovansertib posit
trovagen expect data updat aml prostat cancer
program well potenti colorect cancer posit
deal term term agreement poc capit llc trovagen
issu aggreg common stock seri prefer stock warrant
exercis share common stock per share expir januari
aggreg issu price poc capit fund use
support clinic develop ovansertib clinic studi metastat
colorect cancer patient metastat colorect cancer
surviv rate less patient carri ra mutat
overexpress standard care soc first-lin
set irrespect kra mutat statu includ combin
fu /leucovorin lv either oxaliplatin folfox irinotecan folfiri togeth
monoclon antibodi either vascular endotheli growth factor vegf
avastin bevacizumab epiderm growth factor receptor egfr
cetuximab respons rate treatment efficaci therapi
remain limit particularli kras-mut patient popul importantli
onvansertib shown exhibit synergi irinotecan bevacizumab
preclin studi tumor harbor kra mutat effect clinic
set onvansertib combin soc could potenti prolong surviv
respons difficult-to-treat patient
studi design open-label studi evalu onvansertib
combin soc folfiri avastin mcrpc patient harbor kra
mutat histolog confirm metastat unresect diseas two
center us addit patient must fail treatment intoler
folfox fluoropyrimidin oxaliplatin without avastin dose-
escal portion assess safeti drug combin
mcrpc patient identifi recommend dose portion evalu
respons combin patient mcrc
click full note
maintain buy rais pt better-than-expect
result dividend announc potenti cbd
maintain buy rate coffe hold co jva rais price
target follow releas better-than-expect
jva post better-than-expect ep forecast
despit lower spot coffe price record quarter
rais ep estim ep
estim assum slightli higher organ sale
jva announc talk two cbd cannabidol produc cbd-
infus coffe product revis ep estim assum potenti
manag announc would pay net profit dividend
follow conclus would paid lieu compani
share buy-back program suspend effect immedi
invest thesi remain intact see manag focu shift
increment higher-margin top-lin growth recent acquisit
ep actual vs maxim estim
revenu actual vs maxim estim
gross margin actual vs maxim estim
oper margin actual vs maxim estim
manag provid guidanc financi metric
still believ jva offer attract upsid potenti even today ralli
jva share trade ep estim forward ev/ebitda
upwardli revis price target jva reflect primarili outlook acquisition-
fuel top-lin growth sustain margin expans off-set somewhat near-
term risk lower coffe price equal weight forward price-to-earnings multipl base
discount multipl forward ev/ebitda multipl base discount
multipl forward sale multipl base discount peer multipl
methodolog arriv new price target
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
